Anti-CEP55 Antibody Picoband® FITC Vervoeging

Centrosomal protein of 55 kDa (Cep55), is a protein that in humans is encoded by the CEP55 gene. Enables identical protein binding activity. Involved in cranial skeletal system development; establishment of protein localization; and midbody abscission. Acts upstream of or within mitotic cytokinesis. Located in Flemming body and centrosome. Implicated in multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia and hydranencephaly.

CEP55; C10orf3; URCC6; Centrosomal protein of 55 kDa; Cep55; Up-regulated in colon cancer 6

CEP55

55165

Q53EZ4

Human

No cross-reactivity with other proteins

E.coli-derived human CEP55 recombinant protein (Position: E115-K464) . Human CEP55 shares 76.3% and 78% amino acid (aa) sequence identity with mouse and rat CEP55, respectively.

Flow Cytometry

Immunogen affinity purified.

Liquid

1. Bondeson, M.-L., Ericson, K., Gudmundsson, S., Ameur, A., Ponten, F., Wesstrom, J., Frykholm, C., Wilbe, M. A nonsense mutation in CEP55 defines a new locus for a Meckel-like syndrome, an autosomal recessive lethal fetal ciliopathy. Clin. Genet. 92: 510-516, 2017. 2. Chen, C.-H., Chien, C.-Y., Huang, C.-C., Hwang, C.-F., Chuang, H.-C., Fang, F.-M., Huang, H.-Y., Chen, C.-M., Liu, H.-L., Huang, C.-Y. F. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene 28: 2723-2737, 2009. 3. Chen, C.-H., Lu, P.-J., Chen, Y.-C., Fu, S.-L., Wu, K.-J., Tsou, A.-P., Lee, Y.-C. G., Lin, T.-C. E., Hsu, S.-L., Lin, W.-J., Huang, C.-Y. F., Chou, C.-K. FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway. Oncogene 26: 4272-4283, 2007.

At -20 ̊C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.

54 kDa

6

Centrosomal protein 55

Centrosomal protein of 55 kDa

Rabbit IgG

Each vial contains 50% glycerol, 0.9% NaCl, 0.2% Na2HPO4, 0.02% NaN3.